

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED  
CENTRAL FAX CENTER**In re Application of  
**JOCKERS, et al.**

Examiner: Not Yet Known

**SEP 15 2004**

Application No.: 10/774,721

Art Unit: Not Yet Known

Filed: February 9, 2004

Title: **OLIGONUCLEOTIDES WHICH INHIBIT  
EXPRESSION OF THE OB-RGRP PROTEIN AND  
METHOD FOR DETECTING COMPOUNDS  
WHICH MODIFY THE INTERACTION BETWEEN  
PROTEINS OF THE OB-RGRP FAMILY AND THE  
LEPTIN RECEPTOR****TELEFAX CERTIFICATE**I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

September 15, 2004

Date of Transmission

Signature

*James H. Hare, Jr.***SUBMISSION AND REQUEST FOR ENTRY OF POWERS OF  
ATTORNEY**Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sirs:

Applicants submit herewith three (3) Powers of Attorney for the present patent application.

The Commissioner is hereby authorized to charge any additional fees which may be required by this  
paper, or credit any overpayment, to Deposit Account No. 18-1982. Two (2) duplicate copies of this  
sheet are enclosed.

Respectfully submitted,

*F. Aaron Dubberley*F. Aaron Dubberley, Reg. No., 41,001  
Attorney/Agent for ApplicantAventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3737  
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005 US NP

**BEST AVAILABLE COPY**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED  
CENTRAL FAX CENTER**In re Application of  
**JOCKERS, et al.**

Examiner: Not Yet Known

SEP 15 2004

Application No.: 10/774,721

Art Unit: Not Yet Known

Filed: February 9, 2004

Title: **OLIGONUCLEOTIDES WHICH INHIBIT  
EXPRESSION OF THE OB-RGRP PROTEIN AND  
METHOD FOR DETECTING COMPOUNDS  
WHICH MODIFY THE INTERACTION BETWEEN  
PROTEINS OF THE OB-RGRP FAMILY AND THE  
LEPTIN RECEPTOR****TELEFAX CERTIFICATE**I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

September 15, 2004

Date of Transmission

Signature

**SUBMISSION AND REQUEST FOR ENTRY OF POWERS OF  
ATTORNEY**Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sirs:

Applicants submit herewith three (3) Powers of Attorney for the present patent application.

The Commissioner is hereby authorized to charge any additional fees which may be required by this  
paper, or credit any overpayment, to Deposit Account No. 18-1982. Two (2) duplicate copies of this  
sheet are enclosed.

Respectfully submitted,

F. Aaron Dubberley, Reg. No., 41,001  
Attorney/Agent for ApplicantAventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3737  
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005 US NP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**JOCKERS, et al.**

Examiner: Not Yet Known

**RECEIVED  
CENTRAL FAX CENTER**

Art Unit: Not Yet Known

**SEP 15 2004**

Application No.: 10/774,721

Filed: February 9, 2004

Title: **OLIGONUCLEOTIDES WHICH INHIBIT  
EXPRESSION OF THE OB-RGRP PROTEIN AND  
METHOD FOR DETECTING COMPOUNDS  
WHICH MODIFY THE INTERACTION BETWEEN  
PROTEINS OF THE OB-RGRP FAMILY AND THE  
LEPTIN RECEPTOR**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

September 15, 2004

Date of Transmission

Signature

**SUBMISSION AND REQUEST FOR ENTRY OF POWERS OF  
ATTORNEY**


Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sirs:

Applicants submit herewith three (3) Powers of Attorney for the present patent application.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 18-1982. Two (2) duplicate copies of this sheet are enclosed.

Respectfully submitted,

  
F. Aaron Dubberley, Reg. No., 41,001  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3737  
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005 US NP

Aventis Docket No. FRAV2003/0005USNP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Jockers et al

Examiner: To Be Assigned

Serial No.: 10/774,721

Group Art Unit: Unknown

Filed: February 9, 2004

**Title:** OLIGONUCLEOTIDES WHICH INHIBIT EXPRESSION OF THE  
OB-RGRP PROTEIN AND METHOD FOR DETECTING  
COMPOUNDS WHICH MODIFY THE INTERACTION  
BETWEEN PROTEINS OF THE OB-RGRP FAMILY  
AND THE LEPTIN RECEPTOR

**POWER OF ATTORNEY FOR PATENT APPLICATION**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I, \_\_\_\_\_, an Authorized Signatory of Centre National De La  
Rechercher Scientifique, Assignee of the above-identified Application, hereby appoint the attorneys  
and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full  
power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in  
connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date: February 9, 2004

By: Le Responsable du Pilotage  
de la ValorisationTitle: F. Foubert  
**Frédéric FOUBERT**Date: 04/29/04

Address correspondence and telephone calls to:  
Karen I. Krupen, Reg. No. 34,647  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4797  
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/000SUSNP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Jockers et al.

Examiner: To Be Assigned

Serial No.: 10/774,721

Group Art Unit: Unknown

Filed: February 9, 2004

Title: OLIGONUCLEOTIDES WHICH INHIBIT EXPRESSION OF THE  
OB-RGRP PROTEIN AND METHOD FOR DETECTING  
COMPOUNDS WHICH MODIFY THE INTERACTION  
BETWEEN PROTEINS OF THE OB-RGRP FAMILY  
AND THE LEPTIN RECEPTOR

**POWER OF ATTORNEY FOR PATENT APPLICATION**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I, \_\_\_\_\_, an Authorized Signatory of Institut National De La Sante Et  
De La Recherche Medical, Assignee of the above-identified Application, hereby appoint the  
attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or  
agents with full power to prosecute this application on behalf of Assignee and to transact all of  
Assignee's business in connection with the above-identified Application in the Patent and Trademark  
Office:

Customer No.: 005487

Effective Date: February 9, 2004

By: Christine BERLING  
Directrice Adjointe  
Département Valorisation  
et Transfert de Technologies

Title: \_\_\_\_\_

Date: Pour le Directeur Général et par délégation  
INSERM

INSTITUT NATIONAL de la SANTÉ  
et de la RECHERCHE MÉDICALE  
101, rue de Tolbiac  
75656 PARIS CEDEX 12

Address correspondence and telephone calls to:  
Karen I. Krupen, Reg. No. 34,647  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4797  
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005USNP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Jockers et al.

Examiner: To Be Assigned

Serial No.: 10/774,721

Group Art Unit: Unknown

Filed: February 9, 2004


Title: OLIGONUCLEOTIDES WHICH INHIBIT EXPRESSION OF THE  
OB-RGRP PROTEIN AND METHOD FOR DETECTING  
COMPOUNDS WHICH MODIFY THE INTERACTION  
BETWEEN PROTEINS OF THE OB-RGRP FAMILY  
AND THE LEPTIN RECEPTOR

**POWER OF ATTORNEY FOR PATENT APPLICATION**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I, BOUVET Philippe, an Authorized Signatory of Aventis Pharma S.A.,  
Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated  
with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this  
application on behalf of Assignee and to transact all of Assignee's business in connection with the  
above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date: February 9, 2004By: BOUVET PhilippeTitle: ExecutiveDate: July 29, 2004

Address correspondence and telephone calls to:  
Karen I. Krupen, Reg. No. 34,647  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4797  
Telefax (908) 231-2626

RECEIVED  
CENTRAL FAX CENTER

SEP 15 2004

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:  
FRAV2003/0005 US NPApplicants:  
JOCKERS, et al.Serial No.  
10/774,721Filing Date:  
February 9, 2004

Title of Invention:

## CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450 Patent Application, at 703-872-9306, on  
Date of Deposit September 15, 2004

Printed Name of Person Signing Certificate Jonas Pierre, Sr.

Signature

Total Number of Pages Sent: 7

Attorney: F. Aaron Dubberley  
Reg. No. 41,001  
Group Art Unit: Not Yet Known  
Examiner: Not Yet KnownTO: Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> Submission of Power of Attorney | <input type="checkbox"/> Fee Transmittal             |
| <input checked="" type="checkbox"/> Powers of Attorney (3 pages)    | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Transmittal Letter (3 page)     | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order      | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Maintenance Fee Transmittal                |  |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**